Next Steps to Treat Parkinson’s, Huntington’s and Alzheimer’s Disease
Add bookmark
Next Steps to Treat Parkinson’s, Huntington’s and Alzheimer’s Disease
Add bookmark
Joachim Tedroff, Head of Clinical Science at NeuroSearch Sweden AB, joins Helen Winsor from Pharma IQ, to discuss strategies for optimising clinical development in CNS. First Tedroff outlines what he sees as the major challenges in the development of CNS therapies coming onto the market. In the second part of the interview, he provides an update on NeuroSearch’s recent success with a Phase III clinical trial for Huntington’s Disease patients. He elaborates on the work underway and discusses whether this might open up therapeutic opportunities within Alzheimer's disease.
[inlinead]
Tags:
Joachim Tedroff
NeuroSearch Sweden AB
optimising clinical development
CNS trials
CNS therapies
Parkinson’s
Huntington’s
Alzheimer’s Disease
Phase III clinical trial for Huntington’s Disease
psychiatric disorders
